UNCY
UnicyciveยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
UNCY Profile
Unicycive Therapeutics, Inc.
A biotech company that develops novel treatments for kidney diseases
Biological Technology
08/18/2016
07/13/2021
NASDAQ Stock Exchange
22
12-31
Common stock
4300 El Camino Real, Suite 210, Los Altos, CA 94022
--
Unicycive Therapeutics, Inc., was incorporated in Delaware on August 18, 2016. The company was dormant until July 2017 when it began evaluating some drug candidates for licensing. The company is a biotechnology company that develops treatments for certain medical conditions. Currently, the company's two projects focus on kidney disease. As the company grows and the team is established, the company intends to focus on identifying medical conditions inside and outside kidney disease. The company's current development programs focus on two new therapies: cyanide carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis, and UNI 494 for the treatment of acute kidney injury (AKI).
